|  | Clustering |  |  | Univariate |
---|---|---|---|---|---|
Variable | Level | Unclustered, n = 13 (%) | Clustered, n = 57 (%) | P-value | Odds ratio (95% CI) |
Demographics | |||||
Sex | Female | 6 (46%) | 22 (39%) | 0.789 | Referent |
Male | 7 (54%) | 35 (61%) |  | 1.36 (0.41–4.49) | |
Age groups | Adults (> 17 y) | 12 (92%) | 53 (93%) | 1.000 | Referent |
Children = < 16 y | 1 (8%) | 4 (7%) |  | 0.91 (0.09–8.85) | |
TB/DOTS Facilities | Folang | 0 | 1 (2%) | 0.735 | 1-- |
Kalafong | 5 (38%) | 21 (37%) |  | 0.53 (0.05–5.21) | |
Mamelodi | 1 (8%) | 9 (7%) |  | 1.13 (0.06–21.08) | |
Potchefstroom | 0 | 4 (7%) | Â | 1-- | |
Pretoria West | 1 (8%) | 3 (5%) |  | 0.38 (0.02–8.10) | |
Skinner | 1 (8%) | 1 (2%) |  | 0.13 (0–4.00) | |
Steve Biko | 4 (31%) | 10 (18%) |  | 0.31 (0.03–3.38) | |
Tshwane | 1 (8%) | 8 (14%) | Â | Referent | |
Clinicals | |||||
Any drug resistance | Susceptible | 10 (77%) | 49 (86%) | 0.416 | Referent |
Resistance | 3 (23%) | 8 (14%) |  | 0.54 (0.12–2.42) | |
INH mono-resistance | Susceptible | 13 (100%) | 52 (91%) | 0.576 | 1-- |
Resistance | 0 | 5 (9%) | Â | Â | |
MDR/RIF* | Susceptible | 10 (77%) | 49 (91%) | 0.179 | Referent |
Resistance | 3 (23%) | 5 (9%) |  | 0.34 (0.07–1.66) | |
Disease site | Disseminated | 1 (8%) | 3 (5%) | 0.540 | Referent |
Lymph nodes | 4 (31%) | 16 (28%) |  | 1.33 (0.11–16.48) | |
Meninges | 1 (8%) | 4 (7%) |  | 1.33 (0.06–31.12) | |
EPTB/PTB | 1 (8%) | 2 (4%) |  | 0.67 (0.02–18.06) | |
Pericardium | 0 | 1 (2%) | Â | 1-- | |
Peritoneum | 0 | 5 (9%) | Â | 1-- | |
Pleura | 2 (15%) | 18 (32%) |  | 3 (0.20–44.36) | |
Genitourinary | 0 | 2 (4%) | Â | 1-- | |
Cutaneous TB | 4 (31%) | 6 (11%) |  | 0.5 (0.04–6.68) | |
Beijing Clade | Yes | 0 | 25 (44%) | 0.003 | --1 |
No | 13 (100%) | 32 (56%) | Â | Â | |
Euro-American | No | 12 (92%) | 31 (54%) | 0.011 | Â |
Yes | 1 (8%) | 26 (46%) |  | 10.06 (1.23–82.64) | |
East-Africa-India | No | 13 (100) | 51 (89) | 0.221 | Â |
Yes | 0 | 6 (11%) | Â | --1 |